Regular blood testing for those with CLL and SLL is an important part of managing the disease, as it can provide valuable insights into your overall health.

Integrative medicine is a patient-centered, evidence-informed field of comprehensive cancer care to promote optimal health and well-being.

Tumor lysis syndrome is a rare condition that can happen due to the rapid death of cancer cells.

Autoimmune hemolytic anemia (AIHA) is the most common autoimmune condition associated with CLL and SLL.

Immune thrombocytopenic purpura (ITP) is a rare but serious complication that happens in an estimated 1-5% of those living with CLL and SLL.

Measurable residual disease (MRD) testing measures the amount of cancer cells that are present in blood or bone marrow at the time the sample was collected.

MBL is a condition where there is an accumulation of abnormal B-cells in the blood.

Zanubrutinib may be taken alone as a preferred initial (first-line) treatment, or alone as a second- or third-line treatment.